Chemours Company (The)

Chemours Company (The)

13.79
USD
+0.70
(+5.35%)
-2.01EPS
3.09BMarket Cap
Feb 11Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
37.82
35.46
31.59
29.73
33.45
37.51
33.53
30.17
38.47
45.53
40.82
38.68
38.66
- -
Basic EPS, GAAP
2.33
2.21
-0.5
0.04
4.04
5.62
-0.32
1.33
3.69
3.85
-1.7
0.46
-2.57
- -
Free Cash Flow per Basic Share
1.98
-0.55
-1.86
1.41
1.24
3.63
1.03
3.28
3.26
2.99
1.25
-6.64
0.34
- -
Dividend per Share
- -
- -
0.58
0.12
0.12
0.84
1
1
0.99
1.03
1
0.99
0.52
0.27
Book Value per Share
17.76
20.27
0.7
0.55
4.7
5.94
4.21
4.93
6.71
7.45
4.96
3.82
1.67
- -
Tangible Book Value per Share
16.57
19.12
-0.28
-0.38
3.79
4.88
3.15
3.92
6.04
6.68
4.25
3.49
1.35
- -
Basic Weighted Avg Shares
181
181
181
182
185
177
165
165
165
150
149
149
150
151
Sales/Revenue/Turnover
6,859
6,432
5,717
5,400
6,183
6,638
5,526
4,969
6,345
6,831
6,078
5,782
5,808
- -
Operating Margin (%)
7.76
8.27
3.95
1.41
16.25
18.56
7.46
8.17
10.62
11.51
-2.02
7.28
-0.48
- -
Depreciation Expense
261
257
267
284
273
284
311
320
317
291
309
292
340
- -
Net Income, GAAP
423
400
-90
7
746
995
-52
219
608
578
-253
69
-386
- -
Effective Tax Rate (%)
26.39
27.09
- -
- -
18.09
13.77
- -
- -
10.06
22
- -
34.91
- -
- -
Profit Margin (%)
6.17
6.22
-1.57
0.13
12.07
14.99
-0.94
4.41
9.58
8.46
-4.16
1.19
-6.65
- -
Working Capital
509
543
835
782
1,845
1,584
1,236
1,191
1,487
1,323
1,349
1,197
1,315
- -
LT Debt
- -
- -
3,915
3,529
4,097
3,959
4,271
4,199
3,903
3,788
4,193
4,257
4,290
- -
Total Equity
3,217
3,673
130
104
865
1,020
695
815
1,082
1,107
739
572
251
- -
Return on Invested Capital (%)
11.87
11.48
- -
- -
18.71
20.18
- -
- -
13.45
12.3
- -
4.15
- -
- -
Return on Capital (%)
13.09
11.58
- -
- -
21.34
23.32
- -
- -
15.24
14.02
- -
4.82
- -
- -
Return on Common Equity (%)
13.13
11.62
-4.74
6.19
155.42
106.19
-6.11
29.16
64.2
52.83
-27.44
10.55
-94.03
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
99
91
- -
LT Borrowings
4,100
3,838
- -
LT Finance Leases
192
191
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
150
150
151
Market Capitalization
3,312
3,088
2,043

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,928
3,094
- -
Cash, Cash Equivalents & STI
563
671
- -
Accounts Receivable, Net
645
773
- -
Inventories
1,536
1,452
- -
Total Current Liabilities
1,609
1,861
- -
Payables & Accruals
1,278
1,549
- -
ST Debt
99
91
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
63.82%
-15.38%
-56.12%
Free Cash Flow
-67.49%
-162.92%
-105.14%
Net Income, GAAP
909.86%
-151.55%
-659.42%
Sales/Revenue/Turnover
0.94%
3.98%
0.45%
Total Cash Common Dividend
- -
- -
-47.3%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,362
1,554
1,508
1,394
5,782
2025
1,368
1,615
1,495
1,330
5,808
2026
1,381
1,591
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.36
0.4
-0.21
-0.05
0.46
2025
-0.03
-2.53
0.4
-0.41
-2.57
2026
-0.19
-1.81
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.25
0.25
0.25
0.24
0.99
2025
0.25
0.09
0.09
0.1
0.52
2026
0.09
0.09
- -
- -
- -

Company Description

CEO
Denise M. Dignam
Full Time Employees
5,700
Sector
Process industries
Industry
Chemicals: specialty
Address
1007 Market Street Wilmington DE United States 19801
IPO Date
Jun 19, 2015
Business
The Chemours Company (NYSE: CC), founded in 2015 as a spin-off from DuPont's performance chemicals business and headquartered in Wilmington, Delaware, provides performance chemicals essential for industries including automotive, electronics, energy, coatings, and medical applications. The company operates through three core segments: Titanium Technologies, offering Ti-Pure titanium dioxide pigments for coatings, plastics, and paper; Thermal & Specialized Solutions, producing refrigerants such as Opteon and Freon, foam blowing agents, propellants, and industrial fluoropolymers; and Advanced Performance Materials, supplying fluoropolymer resins and derivatives including Teflon, Viton, Nafion, Krytox, and ECCtreme for semiconductors, batteries, and high-performance applications; alongside chemical solutions like sodium cyanide, sulfuric acid, aniline, and mining intermediates. With approximately 6,000 employees and 29 manufacturing facilities across nine countries, Chemours markets its products in 120 countries, generating $5.8 billion in net sales for 2024. Chemours maintains a global presence in North America, Asia-Pacific, Europe, Middle East, Africa, and Latin America, serving roughly 2,900 customers with a focus on high-growth areas such as data center cooling, next-generation refrigerants, electric vehicles, clean energy, and semiconductor fabrication under its Pathway to Thrive strategy. Recent developments include a March 2025 strategic alliance with Energy Fuels Inc. to bolster U.S. domestic supply chains for rare earth elements, titanium, and zirconium minerals, leveraging complementary mining operations in Florida, Georgia, Madagascar, Brazil, and Australia; and August 2025 agreements with SRF Limited in India for manufacturing high-quality fluoroproducts to enhance supply flexibility without capital investment, supporting essential applications by 2026. The company appointed Denise Dignam as President and CEO, alongside leadership additions like Matthew Conti as Chief Human Resources Officer and Nathan Blom as Vice President of Liquid Cooling Growth Portfolio, amid strategic investments in sustainability such as PFAS emission reductions. Chemours reported third-quarter 2025 net sales of $1.495 billion and continues portfolio optimization through prior divestitures including its mining solutions business in 2021 and glycolic acid business in 2023.

Company News

  • What Chemours (CC) Said on Its Q3 Earnings Call

  • What's Next for The Chemours Company Shareholders After 18.63% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

  • The SEC Just Called Canton Coin a Digital Commodity, Not a Security. What Did Canton Have to Prove to Get That Letter?

  • Levi & Korsinsky Reminds The Chemours Company Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of December 7, 2026 - CC

  • CC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds The Chemours (CC) Investors of Securities Class Action Lawsuit Deadline on December 7, 2026

  • Kaplan Fox Reminds Investors of a Securities Class Action Against The Chemours Company (CC) - Deadline is December 7, 2026

  • CC Class Reminder: Chemours Opteon Demand Issues Trigger Securities Fraud Class Action for Investors – Contact BFA Law if You Lost Money

  • Financial Survey: Chemours (NYSE:CC) vs. Quaker Houghton (NYSE:KWR)

  • The Chemours Company Securities Fraud Class Action Result of Overstatement of Refrigerant Aftermarket Demand and 18% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC

  • Pomerantz Law Firm Announces the Filing of a Class Action Against The Chemours Company and Certain Officers – CC

  • The Chemours Company (CC) Q3 2026 Earnings Call Transcript

  • What Does The Chemours Company's 18.63% Stock Drop Mean for Investors? The Law Offices of Howard G.

  • Bronstein, Gewirtz & Grossman LLC Urges Chemours Company Investors to Act: Class Action Filed Alleging Investor Harm

  • Bronstein, Gewirtz & Grossman LLC Urges Chemours Company Investors to Act: Class Action Filed Alleging Investor Harm

  • CC Investors Have Opportunity to Lead The Chemours Company Securities Fraud Lawsuit with SBS Law

  • What Chemours (CC) Said on Its Q3 Earnings Call

  • CC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in The Chemours Company Securities Lawsuit - Contact SueWallSt

  • Robbins LLP Urges CC Shareholders to Contact the Firm for Information About The Chemours Company Securities Class Action

  • CC Shareholder Notice: Chemours Sued for Securities Fraud over Alleged Misrepresentations to Investors - Class Action Deadline is December 7

  • Chemours: Patient Investors Can Be Rewarded (Rating Upgrade)